News|Articles|March 17, 2025

Updated MIRASOL Data Confirm Efficacy of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

The final data analysis confirmed that mirvetuximab soravtansine-gynx (Elahere; AbbVie) significantly improves progression-free survival, overall survival, and objective response in patients with folate receptor alpha-positive (FRα+) platinum-resistant ovarian cancer.

Mirvetuximab soravtansine-gynx (Elahere; AbbVie) continued to demonstrate superior clinical benefits in patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer in the final analysis of the phase 3 MIRASOL trial (NCT04209855), as presented in a late-breaking session at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer on Saturday.¹